Literature DB >> 23801406

Analysis of progression and recurrence of meningioma using (11)C-methionine PET.

Hidetoshi Ikeda1, Naohiro Tsuyuguchi, Noritsugu Kunihiro, Kenichi Ishibashi, Takeo Goto, Kenji Ohata.   

Abstract

OBJECTIVE: The recurrence rate of meningioma after surgery is high, and progression is often observed. The risk factors for recurrence and progression are not clear. We evaluated the risk factors for recurrence and progression in meningioma using (11)C-methionine (MET) positron emission tomography (PET).
METHODS: Thirty-seven patients (mean follow-up, 80 months) with an intracranial meningioma were enrolled. MET PET was performed before treatment between 1995 and 2010, and patients were followed up in an out-patient clinic. Surgery was performed in 33 patients, and a wait-and-see approach was taken in four patients. We evaluated the extent of tumor resection, location, WHO grade, Ki-67 labeling index, and lesion to normal ratio (LN ratio) of MET uptake.
RESULTS: Six of the surgical cases had a recurrence, and two of the observation-only patients had tumor progression. A high LN ratio of MET uptake was a significant risk factor for recurrence and progression with univariate analysis. The area under the curve of receiver operating characteristic curve for the LN ratio of MET uptake was 0.754, and the optimal cutoff value was 3.18 (sensitivity 63 %, specificity 79 %). With multivariate analysis, a high LN ratio of MET uptake, non-gross total resection, and a high WHO grade were significant risk factors for progression and recurrence.
CONCLUSION: A high LN ratio of MET uptake was a risk factor for tumor progression and recurrence. The advantage of MET PET is that it is not invasive and can easily be used to evaluate the whole tumor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801406     DOI: 10.1007/s12149-013-0747-z

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

Review 1.  Diagnostic challenges in meningioma.

Authors:  Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

2.  Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.

Authors:  Edit Bosnyák; David O Kamson; Anthony R Guastella; Kaushik Varadarajan; Natasha L Robinette; William J Kupsky; Otto Muzik; Sharon K Michelhaugh; Sandeep Mittal; Csaba Juhász
Journal:  Neuro Oncol       Date:  2015-06-18       Impact factor: 12.300

Review 3.  PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors:  Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

4.  Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.

Authors:  Mats Ryttlefors; Torsten Danfors; Francesco Latini; Anders Montelius; Erik Blomquist; Olafur Gudjonsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

5.  Transcriptome signatures associated with meningioma progression.

Authors:  Angela N Viaene; Bo Zhang; Maria Martinez-Lage; Chaomei Xiang; Umberto Tosi; Jayesh P Thawani; Busra Gungor; Yuankun Zhu; Laura Roccograndi; Logan Zhang; Robert L Bailey; Phillip B Storm; Donald M O'Rourke; Adam C Resnick; M Sean Grady; Nadia Dahmane
Journal:  Acta Neuropathol Commun       Date:  2019-04-30       Impact factor: 7.801

Review 6.  Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.

Authors:  K Mariam Slot; Dagmar Verbaan; Dennis R Buis; Linda J Schoonmade; Bart N M Berckel; W Peter Vandertop
Journal:  J Neuroimaging       Date:  2020-11-02       Impact factor: 2.486

Review 7.  Use of advanced neuroimaging and artificial intelligence in meningiomas.

Authors:  Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

8.  Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Tomo Miyata; Taichiro Toho; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  Radiat Oncol       Date:  2015-07-30       Impact factor: 3.481

Review 9.  Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

Authors:  Riccardo Laudicella; Domenico Albano; Salvatore Annunziata; Diletta Calabrò; Giovanni Argiroffi; Elisabetta Abenavoli; Flavia Linguanti; Domenico Albano; Antonio Vento; Antonio Bruno; Pierpaolo Alongi; Matteo Bauckneht
Journal:  Cancers (Basel)       Date:  2019-09-22       Impact factor: 6.639

10.  Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY).

Authors:  Hanne-Rinck Jeltema; Marnix R Jansen; Adriaan R E Potgieser; Antoinette D I van Asselt; Mart A A M Heesters; Anouk van de Hoorn; Andor W J M Glaudemans; J Marc C van Dijk
Journal:  Neuroradiology       Date:  2021-03-10       Impact factor: 2.804

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.